The mixed top-line results from two Phase III studies of Gilead Sciences Inc.’s Janus kinase (JAK) 1/2 inhibitor, momelotinib, in myelofibrosis lifts the prospects of competitors marketing products for this difficult-to-treat disease.
Gilead's Late-Stage R&D Misfire Gives Respite To Competing Myelofibrosis Therapies
The JAK inhibitor momelotinib meets some endpoints but misses others in two late-stage clinical studies in myelofibrosis, a condition that has proved recalcitrant to various new approaches, leaving Incyte/Novartis’s marketed product ruxolitinib as one of the few successes.